Matches in SemOpenAlex for { <https://semopenalex.org/work/W71288051> ?p ?o ?g. }
Showing items 1 to 78 of
78
with 100 items per page.
- W71288051 abstract "OBJECTIVE: The objective of this selective EBM review is to determine “Is famciclovir superior to valacyclovir as a treatment for recurrent genital herpes in reducing outbreak duration and frequency?” STUDY DESIGN: This review is based on three double-blind, randomized controlled trials (RCTs) published in 2006, 2008, and 2009. The studies compared the efficacy and safety of famciclovir (FCV) vs. valacyclovir (VCV) in the treatment of genital herpes. DATA SOURCES: All articles used were published in English, in peer-reviewed journals, and found using PubMed. OUTCOMES MEASURED: The effectiveness of famciclovir and valacyclovir was evaluated based on the proportion of patients with aborted lesions, the time to resolutions of lesions of active infection and all associated symptoms, the time to next reoccurrence, and the proportion of patients with a recurrence. RESULTS: All three studies found that there were no significant differences in efficacy or safety in terms of clinical disease manifestations between FCV and VCV. Median time to healing of herpes lesions was similar in both groups (4.25 days vs. 4.08 days), and about onethird of patients in both groups experienced aborted lesions. A follow-up study showed similar times to next recurrence (33.5 days vs. 38 days). Values for evaluating frequency of recurrences proved to be similar as well, with 34% of the FCV group and 28% of the VCV group experiencing an outbreak within a 16-week post-treatment period, and the mean number of recurrences being 0.11 and 0.10, respectively. CONCLUSIONS: The results of the three RCTs demonstrate that famciclovir is equally effective compared to valacyclovir, but does not appear to be superior in treating genital herpes. However, the shorter dosing schedule of famciclovir for herpes recurrence may provide a more convenient treatment option for some patients, and further comparative studies are warranted to investigate whether improvements in virologic disease manifestations from previous in vivo murine studies translate into clinically meaningful results." @default.
- W71288051 created "2016-06-24" @default.
- W71288051 creator A5070505032 @default.
- W71288051 date "2014-01-01" @default.
- W71288051 modified "2023-09-26" @default.
- W71288051 title "Is Famciclovir Superior to Valacyclovir as a Treatment for Recurrent Gential Herpes in Reducing Outbreak Duration and Frequency" @default.
- W71288051 cites W1971851172 @default.
- W71288051 cites W1980891252 @default.
- W71288051 cites W2010704966 @default.
- W71288051 cites W2012654104 @default.
- W71288051 cites W2057280407 @default.
- W71288051 cites W2060459066 @default.
- W71288051 cites W2091338654 @default.
- W71288051 cites W2144823341 @default.
- W71288051 cites W2166754591 @default.
- W71288051 hasPublicationYear "2014" @default.
- W71288051 type Work @default.
- W71288051 sameAs 71288051 @default.
- W71288051 citedByCount "0" @default.
- W71288051 crossrefType "journal-article" @default.
- W71288051 hasAuthorship W71288051A5070505032 @default.
- W71288051 hasConcept C116675565 @default.
- W71288051 hasConcept C126322002 @default.
- W71288051 hasConcept C141071460 @default.
- W71288051 hasConcept C142724271 @default.
- W71288051 hasConcept C16005928 @default.
- W71288051 hasConcept C168563851 @default.
- W71288051 hasConcept C187212893 @default.
- W71288051 hasConcept C203014093 @default.
- W71288051 hasConcept C2522874641 @default.
- W71288051 hasConcept C2776409557 @default.
- W71288051 hasConcept C2776723293 @default.
- W71288051 hasConcept C2780452071 @default.
- W71288051 hasConcept C2780727368 @default.
- W71288051 hasConcept C535046627 @default.
- W71288051 hasConcept C71924100 @default.
- W71288051 hasConceptScore W71288051C116675565 @default.
- W71288051 hasConceptScore W71288051C126322002 @default.
- W71288051 hasConceptScore W71288051C141071460 @default.
- W71288051 hasConceptScore W71288051C142724271 @default.
- W71288051 hasConceptScore W71288051C16005928 @default.
- W71288051 hasConceptScore W71288051C168563851 @default.
- W71288051 hasConceptScore W71288051C187212893 @default.
- W71288051 hasConceptScore W71288051C203014093 @default.
- W71288051 hasConceptScore W71288051C2522874641 @default.
- W71288051 hasConceptScore W71288051C2776409557 @default.
- W71288051 hasConceptScore W71288051C2776723293 @default.
- W71288051 hasConceptScore W71288051C2780452071 @default.
- W71288051 hasConceptScore W71288051C2780727368 @default.
- W71288051 hasConceptScore W71288051C535046627 @default.
- W71288051 hasConceptScore W71288051C71924100 @default.
- W71288051 hasLocation W712880511 @default.
- W71288051 hasOpenAccess W71288051 @default.
- W71288051 hasPrimaryLocation W712880511 @default.
- W71288051 hasRelatedWork W1521805145 @default.
- W71288051 hasRelatedWork W1905573993 @default.
- W71288051 hasRelatedWork W1964706293 @default.
- W71288051 hasRelatedWork W2012654104 @default.
- W71288051 hasRelatedWork W2029918571 @default.
- W71288051 hasRelatedWork W2061199151 @default.
- W71288051 hasRelatedWork W2074638826 @default.
- W71288051 hasRelatedWork W2078279237 @default.
- W71288051 hasRelatedWork W2096781389 @default.
- W71288051 hasRelatedWork W2109860701 @default.
- W71288051 hasRelatedWork W2119534420 @default.
- W71288051 hasRelatedWork W2144823341 @default.
- W71288051 hasRelatedWork W2158661396 @default.
- W71288051 hasRelatedWork W2337817865 @default.
- W71288051 hasRelatedWork W2381479923 @default.
- W71288051 hasRelatedWork W2418974741 @default.
- W71288051 hasRelatedWork W2537678808 @default.
- W71288051 hasRelatedWork W2758566124 @default.
- W71288051 hasRelatedWork W69528104 @default.
- W71288051 hasRelatedWork W2188639868 @default.
- W71288051 isParatext "false" @default.
- W71288051 isRetracted "false" @default.
- W71288051 magId "71288051" @default.
- W71288051 workType "article" @default.